{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-129507","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2024-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.134842+00:00","generated_at":"2026-05-29T20:51:48.411235+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iterum Therapeutics regains Nasdaq compliance, hearing cancelled","bullets":["Nasdaq confirmed Iterum cured its Listing Rule 5550(b) deficiency; previously scheduled Nov 21 hearing cancelled.","Company will continue trading on Nasdaq Capital Market; avoids potential delisting.","CEO Corey Fishman expressed commitment to adhere to listing requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-129507","json":"https://secwatch.observer/filing/0000950170-24-129507.json","markdown":"https://secwatch.observer/filing/0000950170-24-129507.md","text":"https://secwatch.observer/filing/0000950170-24-129507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024129507/0000950170-24-129507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024129507/itrm-20241120.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T20:51:48.411235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}